, a known neuroprotective agent exhibiting the properties of both an inhibitor of monoamine oxidase (brain selective) and an inhibitor of acetylcholinesterase was administered to seven old rhesus monkeys well trained to perform versions of a delayed matching-to-sample (DMTS) task. An increasing dose regimen of TV3326 was administered orally according to a schedule that allowed the animals to perform the standard DMTS task and a self-titrating version of the DMTS task each week during the study. A distractor version of the task was administered during two of the doses of TV3326. Under the conditions of this experiment TV3326 failed to significantly affect accuracy on the standard DMTS task; however, the drug was very effective in improving the ability of subjects to titrate to longer-duration delay intervals in the titrating version of the task. The maximal drug-induced extension of the self-titrated delay interval amounted to a 36.7% increase above baseline. This increase in maximum delay duration occurred without a significant change in overall task accuracy. TV3326 also significantly improved task accuracy during distractor (interference) sessions. The compound was effective enough to return group performance efficiency to standard DMTS vehicle levels of accuracy. These results were independent of whether trials were associated with a distractor or non-distractor delay interval, and they were independent of delay interval. The lack of delay selectivity in task improvement by TV3326 may not be consistent with a selective effect on attention. TV3326 was not associated with any obvious side effect or untoward reaction of the animals to the drug. Thus, TV3326 may be expected to offer a significant positive cognitive outcome in addition to its reported neuroprotective action.
The well-known selective vulnerability of basal forebrain acetylcholine-containing neurons in Alzheimer's disease has underscored the importance of this neurotransmitter system in certain components or types of working memory and perhaps in other behavioral and cognitive functions affected by the disease. Among the host of degenerative processes occurring in Alzheimer's disease, reproducible cholinergic deficits have been consistently reported, they appear early in the disease process, and correlate well with the degree of dementia (for review, Francis et al., 1999) . Moreover, abnormalities in cholinergic function are frequently reported in other degenerative conditions such as Parkinson's disease, diffuse Lewy body dementia and Huntington's disease. As in Alzheimer's disease, such cholinergic deficits often correlate with memory decline and dementia. The use of cholinesterase inhibitors such as donepezil and rivastigmine provide the bulk of the clinical armamentarium for the treatment of cognitive symptoms in the treatment of Alzheimer's disease. These drugs have provided reasonable effectiveness in mild to moderate cases, improving quality of life and a delay in symptomatic progression of the disease, in the case of donepezil, by up to 55 weeks (Taylor, 2001) . Despite their effectiveness as cognition enhancers, thus far cholinesterase inhibitors have not been shown to significantly impact the neurodegenerative process itself. Other disease-modifying approaches to the treatment of Alzheimer's disease are under intense investigation (see Jacobsen, 2002; Taylor et al., 2002) . One of these includes the ability to offer a degree of neuroprotection, i.e. to support and possibly repair dystrophic neurons, and to enhance neuronal outgrowth and synaptic sprouting. Whereas the use of selective monoamine oxidase-B (MAO-B) inhibitors such as selegiline have been tested in Parkinson's patients and found to be only partially effective in slowing the progress of the disease (Parkinson Study Group, 1989) , this class of agent may offer neuroprotection in Alzheimer's disease (Sano et al., 1997; Knoll, 2000; Pratico and Delanty, 2000) . TV3326 is a compound combining properties as a CNSselective MAO inhibitor and a cholinesterase inhibitor. Initial preclinical studies with the parent compound, rasagiline, revealed potent cytoprotective activity in vitro, that was attributed to an anti-apoptotic activity (Maruyama et al., 2001 ). The anti-apoptotic and neuroprotective actions of rasagiline and TV3326 were shown to be independent of their ability to inhibit MAO-B, but dependent upon the propargyl moiety component of their structure ). In the same study, administration of TV3326 to mice was demonstrated to reduce the edema and behavioral deficits produced by closed head injury in mice. Chronic administration of the drug also reversed the specific damage to the neurons in the fornix and corpus callosum produced after central injection of streptozotocin in rats (Weinstock et al., 2000a) . In view of the multi-potential (neuroprotectant and cholinesterase inhibitor) of TV3326, the purpose of this study was to determine whether the drug could improve age-dependent cognitive impairment in aged non-human primates.
A wide variety of animal models and behavioral techniques has been applied to the study of drugs that affect memory. Animals of advanced age, usually rodents and non-human primates, have provided a good level of predictability for the clinical efficacy of proposed therapeutics (Arnsten et al., 1996; Paule et al., 1998; Bartus, 2000) . In fact, many drug-discovery programs continue to use rodents in general screening procedures for identifying potential cognitive enhancing agents, electing to continue testing potential lead compounds in non-human primates. Our experience has been that evaluation of such compounds in non-human primates allows for a greater level of predictability in terms of clinical potency and efficacy as compared with lower species (Buccafusco and Terry, 2000) . Various operant tasks, usually food-motivated, allow for the measurement of abilities which are relevant to human aging such as attention, strategy formation, reaction time in complex situations and memory for recent events (e.g. Irle, 1987; Paule et al., 1998; Paule, 2001) . Aged monkeys generally are impaired in their ability to attain efficient performance of these tasks, and they often exhibit a reduced level of task efficiency relative to their younger cohorts (Buccafusco et al., 2002) . TV3326 was administered as a chronic escalating regimen by voluntary oral administration to seven aged rhesus monkeys. The animals were well trained in the performance of three versions of the delayed matching-to-sample (DMTS) task with the object of assessing the effect of the drug on working memory, attention, and psychomotor speed.
EXPERIMENTAL PROCEDURES Study subjects
Seven rhesus macaques were well trained (Ͼ100 individual sessions) in the DMTS task. The animals were maintained on tap water (unlimited) and standard laboratory monkey chow (Harlan Teklad Laboratory 20% monkey diet, Madison, WI, USA) supplemented with fruits and vegetables. The animals were maintained on a feeding schedule such that approximately 15% of their normal daily (except weekends) food intake was derived from 300 mg reinforcement food pellets (commercial composition of standard monkey chow and banana flakes, Noyes Precision food pellets, P. J. Noyes Co., Lancaster, NH, USA) obtained during experimental sessions. The remainder was made available following each test session. On weekends the animals were fed twice per day. At least a 4-week washout period preceded the initiation of this study. The monkeys were maintained on a 12-h light/dark cycle and were tested each weekday between 09:00 and 14:00 h. Room temperature and humidity were maintained at 72Ϯ1°C and 52Ϯ2%, respectively. All experimental procedures were reviewed and approved by the Medical College of Georgia Institutional Animal Care and Use Committee and are consistent with AAALAC guidelines. The minimal number of animals was used and every effort was taken to minimize their discomfort during the study. Subject demographics are presented in Table 1 . In addition to the information provided in Table 1 , each of the subjects had participated in one or more previous studies in which potential cognitive enhancing agents were evaluated. The drugs in question were proprietary agents and so no description of their pharmacological properties can be disclosed, other than they were short-acting compounds, and they were administered during acute studies no more than twice per week. No side effects or long-lasting effects were associated with any of these earlier studies, and all animals were provided at least a 4-week washout period prior to the present series. Finally, the aged female animals in the study were perimenopausal, i.e. still cycling, but infrequently. All testing was administered between menstrual cycles.
Drug administration
The solid compound (N-propargyl-(3R)-aminoindan-5-yl)-ethyl, methyl carbamate (TV3326) was stored in a tightly stoppered polypropylene vial in a desiccator cabinet at room temperature. No other precautions were used for compound storage. On each day of the experiment, appropriate amounts of drug were weighed to the nearest 0.1 mg and placed in a cocoa mixture for oral administration. Previous experience has shown that a cocoa mixture helps to disguise the potential taste and texture of test compound, and the animals readily consume the dose. To prepare the cocoa mixture, approximately 4 g baking cocoa (commercial supermarket brand) is combined with 9 g of confectioner's powdered sugar. Water is added to consistency (1-1.5 ml). Test compound is added directly to the mixture that is formed into a ball (soft, non-sticky consistency) of about 2 cm in diameter. In each instance drug or vehicle administration occurred 2 h prior to DMTS testing. Initially administration of an 8 mg/kg test dose resulted in several subjects refusing to consume this dose, and certain of our test subjects were able to detect the presence of drug in the vehicle at about the 6 mg/kg level. In order to maintain dosing, we used two strategies: (1) to divide the dose into two vehicle administrations within 5 min of each other; or (2) to provide the drug in about 15 ml of orange juice. Despite our best efforts, only four subjects completed the entire regimen. The other three animals refused to consume the dose as soon as they detected the taste and/or texture of the drug in the mixture. For data presentation in the following figures, the change from Nϭseven to Nϭfour is always noted.
Standard DMTS task
All test panels, computer interfaces, and computer software for data acquisition were developed and are maintained by the Medical College of Georgia Department of Biomedical Engineering (Augusta, GA, USA). Animals were tested simultaneously in their home cages using a computer-automated training and testing system which measures and categorizes the percent correct at each delay, and the latency of response at each step of each matching problem. The computer and operator were isolated from the subjects. Daily sessions consisted of 96 trials. A trial began by illumination of a sample key with one of three colored discs. Monkeys were trained to depress the illuminated sample key to initiate a trial. This action also terminated the illumination of the sample key during a computer-specified delay interval. Following the delay interval, the two choice keys, but not the sample key, were illuminated. One of the two choice keys is presented as the same color as the sample key had been prior the delay, while the other (incorrect) choice key is presented as one of the two remaining colors. If the monkey matched (i.e. pressed the choice key whose color matched that of the stimulus key), that response was rewarded. The inter-trial interval was always 5 s. Several testing precautions were incorporated into the presentation of the matching problem. First, the various combinations of stimulus color (red, green, yellow) were arranged so that each of the three colors appeared an equal number of times as a sample, each color appeared an equal number of times on the two choice keys, and each color appeared an equal number of times in combination with each other color. Likewise, when two colors (e.g. green/yellow) appeared in combination, each color was counterbalanced between left and right in a non-predictable pattern. Thus, correct responses were arranged so that simplistic strategies such as position preference, left/right alternation, or even double left/right alternation resulted in performance at precisely the chance (50%) level. Finally, all stimulus counterbalancing procedures were matched to length of delay. Monkeys exhibit individual capabilities to maintain matching performance following various delay intervals, and the longest delay chosen for a particular monkey is that which consistently allows correct matching at just above chance levels (approximately 60% correct). In general, the length of delay interval was adjusted until three levels of performance difficulty were found: 1) the least difficult zero delay (meanϭ85-100% correct); 2) a short delay interval (means ranging from 75-84% correct); 3) a medium delay interval (means ranging from 65-74% correct) and 4) a long delay interval representing each animal's limit in terms of DMTS performance (55-64% correct). "Zero"-delay is included as a control to monitor for changes in reference memory and/or other potential non-mnemonic changes in task performance. Values obtained for each difficulty level were averaged and recorded as the mean percent correct for the respective interval. Baseline data were obtained following the administration of drug vehicle.
Titrating version of the DMTS task
The paradigm requires the animals to perform a 96-trial session. Subjects begin the first trial with a 0-s delay interval. If that trial was answered correctly, the next trial presented a 1-s delay interval. The 1-s incremental progression was maintained until the subject made an incorrect match. The delay interval for the trial after an incorrect match was always decreased by 1 s. After an incorrect match, if the next trial was answered correctly, then the subsequent trial presented a delay interval 1 s longer in duration. Dependent variables included the overall percentage of trials answered correctly, the number of trials to reach the maximal delay interval attained, and the maximum and average delay interval attained (in seconds).
DMTS with distractor trials
Test sessions with distractors (interference sessions) were conducted on three occasions during the study (during vehicle administration, and during administration of the 5 and 7 mg/kg doses of TV3326). Distractor sessions were kept to a minimum so as to avoid the animals becoming tolerant to the distractor (Prendergast et al., 1998a) . Distractor stimuli were presented to the test subject on 18 of the 96 trials completed during distractor DMTS sessions. The stimuli were presented simultaneously on the sample and choice keys for 3 s and they consisted of a random pattern of the three colored lights flashing in an alternating manner. The distractor lights were comprised of the same three colors used for sample and choice stimuli presentation. The total duration of onset for a given colored light was 0.33 s. Immediately as one colored light was extinguished, a different colored light was presented. Thus, during presentation of the distractor, each color was presented in random order on each key three separate times. Distractor stimuli were present an equal number of times on trials with short, medium, and long delay intervals. The remaining trials were completed with no delay interval or distractor and they are randomly placed throughout the test session.
Statistical analyses
The following parameters were recorded for all trials during all test sessions (i.e. 96 trials per session): percent correct on trials with zero, short, medium, and long delay intervals and task latencies. Data for percent correct were subdivided according to delay interval for each 24-trial delay component of the session. Four task latencies (collapsed across delays) for trials associated with correct and incorrect choices were recorded: sample latencies (time interval between presentation of the sample stimulus and the subject pressing the sample key) and choice latencies (time interval between presentation of the choice stimuli and the subject pressing a choice key). For the titrating version of the task additional variables included the number of trials to maximum delay interval, the maximal delay interval attained, and the average delay interval attained. All statistical analyses were performed on raw data (percent trials correct or median latencies in seconds). Data were analyzed by use of a multi-factorial analysis of variance with repeated measures (SAS Institute Inc., Cary, NC, USA, JMP statistical software package). Fig. 1 presents the performance efficiencies (percentage of the trials completed that were correctly answered) exhibited by the subjects tested 2 h after administration of vehicle as the first seven data points (Table 2) . Increasing the duration of delay (retention) intervals from Zero to Long was associated with the expected decrement in performance efficiency (also shown in Table 2 ). Task accuracy over consecutive days was relatively stable across all delay intervals. Fig. 1 also shows the composite data set for 
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In addition to the effect of drug treatment on task accuracy, aspects of working memory associated with the DMTS task, the two task latencies, also were determined. These values are presented in Table 3 . There was a trend Each value represents the meanϮS.E.M. for 49 determinations (seven per subject). Average refers to the average level of accuracy determined from all completed trials in a session. For the standard delayed matching-to-sample task, including all sessions together, there was a significant effect of "delay interval," independent of treatment (F 3,814 ϭ6.90, PϽ0.0001). toward a significant difference in the latency category, independent of drug treatment (F 3, 814 ϭ2.53, PϽ0.065) . Perusal of the data indicates that, on average, there was an increase in choice latencies associated with incorrect choices over choice latencies associated with correct choices. The observation that subjects take longer to make incorrect choices relative to correct choices is a common finding in these types of studies. Drug treatment did not significantly alter this relationship (F 36,814 ϭ0.84, Pϭ0.74). Fig. 2 summarizes the data derived from testing during sessions in which subjects were required to self-titrate to a maximum delay interval. Task accuracies (percent trials correct) exhibited by the study group during treatment sessions were not significantly different from vehicle (0 mg/kg) sessions (F 9, 44 ϭ1.77, Pϭ0.10) . This finding paralleled the lack of effect on task accuracy obtained during Fig. 2 . Effect of daily single dose administration of TV3326 on performance of the titrating version of the DMTS task measured 2 h after drug administration presented as a function of dose (and experimental day). Task accuracy (percent trials correct) during treatment sessions did not exhibit a significant difference from vehicle (0 mg/kg) days (F 9,44 ϭ1.77, Pϭ0.10), nor was there a significant effect of treatment for the number of trials to attain the maximal delay interval (F 9, 44 ϭ1.36, Pϭ0.24) . In contrast, TV3326 treatment resulted in self-titration to increased durations of both the average and the maximum delay intervals (F 9, 44 ϭ3.73, Pϭ0.0015 and F 9, 44 ϭ3.67, Pϭ0.0017, respectively). * indicates a significant difference from vehicle (0 dose) means (at least PϽ0.04). For the last three doses, Nϭ4.
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the standard DMTS sessions. Although there was a gradual increase in the average number of trials to attain the maximal delay interval (particularly during the higher-dose sessions) the effect of drug treatment again was not statistically significant (F 9, 44 ϭ1.36, Pϭ0.24) . In contrast, TV3326 treatment resulted in self-titration to significantly increased durations as reflected in both the average and the maximum delay intervals attained (F 9,44 ϭ3.73, Pϭ0.0015 and F 9,44 ϭ3.67, Pϭ0.0017, respectively). This increase in task performance was generally sustained from 4-7 mg/kg. The final titrating session was run with no drug administered prior to the task. The data show a rapid return to baseline levels of titrated delay duration (Fig. 2) , supporting the concept that the enhanced response obtained during the TV3326 regimen was not simply an artifact, and, that the drug did not maintain its pharmacological effect long after discontinuation of the chronic regimen. Fig. 3 summarizes the effect of TV3326 on subjects' performance of the distractor version of the DMTS task. Data are presented for non-distractor trials and for distractor trials (3-s duration initiated 1 s after the start of the delay interval). Although the dosing schedule was as described in Figs. 1 and 2, this version of the task was administered only during one vehicle session (experimental day 2), dur- Fig. 3 . Effect of daily single dose administration of TV3326 on performance of the distractor version of the DMTS task measured 2 h after drug administration categorized by delay interval (ZϭZero, SϭShort, M or MedϭMedium, LϭLong). Data are presented for Non-distractor Trials and for Distractor Trials (3-s duration initiated 1 s after the start of the delay interval). Although the dosing schedule was as described in Figs. 1 and 2, this version of the task was administered only during one vehicle session (experimental day 2), during one of the 5 mg/kg doses (experimental day 37), and during one of the 7 mg/kg doses (experimental day 60). Note: only 4 subjects received in the 7 mg/kg dose. For comparison purposes, the baseline accuracy for the standard version of the DMTS task is presented in Panel A. The results derived from distractor sessions run after the two doses are presented in Panel B. There was no significant effect of drug treatment either alone, or as a factor with delay interval. There was a trend (*) toward improvement in overall accuracy (F 2,87 ϭ2.85, Pϭ0.064), i.e. combined distractor and non-distractor trials, and independent of delay (Panel C).
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ing one of the 5 mg/kg doses (experimental day 37), and during one of the 7 mg/kg doses (experimental day 60). For these three sessions the non-distractor trials appeared to be performed as inefficiently (decrements in accuracy relative to standard DMTS levels of performance efficiency) as were the 18 randomly presented distractor trials. We have noted carryover of the distractor-related impairment to non-distractor trials within the same session on other occasions, but the effect seems to be more pronounced in older subjects. Therefore, the results obtained under these conditions should be interpreted with care. Notwithstanding this cautionary note, sessions run after administration of TV3326, independent of dose, independent of delay interval, and independent of trial type (distractor versus non-distractor) showed a trend toward a significant level of improvement in overall accuracy (F 2,87 ϭ2.85, Pϭ0.064).
DISCUSSION
Although MAO inhibitors have been examined for their ability to protect against the development of MPTP-induced parkinsonian symptoms or in reversing symptoms in these animals (e.g. Andringa and Cools, 2000; Kupsch et al., 2001) , very little is known regarding the effects of these compounds on cognitive function in non-human primates. It is known, however, that noradrenergic neurons are necessary for certain frontal lobe-mediated cognitive processes. These include attention and the prevention of distraction in the presence of irrelevant stimuli (Robbins and Everitt, 1995) . A normal level of noradrenergic neural activity appears to be necessary for optimal function of the prefrontal cortex. Agonists at ␣ 2A receptors (e.g. clonidine, guanfacine) have been shown to improve prefrontal cortical function in non-human primates whereas antagonists at ␣ 2 receptors (e.g. yohimbine) have been shown to impair function and to antagonize the positive mnemonic actions of agonists (see Mao et al., 1999) . Thus, the susceptibility to distracting stimuli known to occur in Alzheimer's disease patients may be improved by compounds designed to optimize noradrenergic activity within the prefrontal cortex. Because of the behavioral effects of amphetamine and its derivatives, it is unlikely that this class of drugs could be used as a treatment adjunct in Alzheimer's disease. However, the mood-elevating aspects and potential cognitive enhancing effects of MAO inhibitors may prove more appropriate in this setting. To suggest this possibility for TV3326 are the results of behavioral studies in rats in which chronic administration of TV3326 reversed immobility in the forced swim test (antidepressant activity) and the drug antagonized scopolamine-induced impairment of spatial memory (Weinstock et al., 2000b) . It is undetermined whether this potential positive effect on cognition in these animals was mediated through brain MAO inhibition or through cholinesterase inhibition, or by the combination of effects. Studies in rats (Haroutunian et al., 1990) and macaques Terry et al., 1993) have indicated the advantage of combining the effects of central ␣ 2 adrenergic receptor stimulation (clonidine) with cholinesterase inhibition (physostigmine). It also has not been determined whether the pharmacological actions of TV3326 would include increased brain noradrenergic, dopaminergic, or serotonergic activity at clinically relevant doses. However, in this study, the drug appeared to behave less like a noradrenergic agonist (Jackson and Buccafusco, 1991) , and more like a dopaminergic agonist (Prendergast et al., 1998a) . This is because TV3326 was more effective in improving task accuracy in the distractor version of the DMTS task as compared with the standard version. The role of brain dopaminergic pathways in attentional aspects of cognition is well known. In fact, normal dopaminergic function appears to be necessary for the successful performance of memory tasks that rely on the function of the prefrontal cortex. For example, a narrow range of the D 1 selective agonists A77636 and SKF81297 were reported to improve performance of a spatial working memory task in aged monkeys (Cai and Arnsten, 1997) . For MAO inhibitors, the mechanism for their effects on cognition is even less obvious, in that they may be mediated through mechanisms other than inhibition of the MAO enzyme (Gelowitz et al., 1994; Shankaranarayana et al., 1999) .
The increase in self-titrated maximal delay interval from vehicle levels (22.6 s) to those obtained after administration of the second of the 6 mg/kg doses (30.9 s) in the titrating version of the DMTS task amounted to a 36.7% increase above baseline (in fact, the improvement over baseline that was sustained by the 4 -7 mg/kg doses in the titrating version of the DMTS task averaged 25.2Ϯ4.96% of control). This increase in maximum delay duration occurred with a small, but non-significant, increment in the number of trials needed to attain the longer intervals associated with drug treatment. Also, overall task accuracy was unchanged. The observation that subjects self-titrated to longer delay intervals without a significant change in overall accuracy may indicate that the drug enhanced the motivational aspects of the task. Other behavioral approaches would be needed to confirm this conjecture. Because the average titrated delay interval increased concomitantly with the maximal delay, it is likely that once the maximal delay was attained, accuracy was not sustained for the next few trials, thus maintaining accuracy constant. Nevertheless, we have demonstrated that the titrating DMTS task is more sensitive to age-related task deficits than is the standard DMTS task. Even within the titrating DMTS the scores for session accuracy were not as well correlated with age as was the number of trials to reach the maximal delay interval (Buccafusco et al., 2002) . Thus we interpret an increase in titrated delay interval (as long as accuracy does not decrease) as a positive effect on task performance. TV3326 also significantly improved task accuracy during distractor sessions. The compound was effective enough to return group performance efficiency to standard DMTS vehicle levels of accuracy. These results were independent of whether trials were associated with a distractor or non-distractor trial, and they were independent of delay interval. Because of the profound carryover effect of the distractor-impaired performance to the non-distractor trials, the positive overall effect produced by the compound on task accuracy is difficult to interpret. Drugs like methylphenidate and nicotine generally affect task accuracy selectively during Short delay trials in the distractor task (Prendergast et al., 1998a,b) although like TV3326, nicotine improved task accuracy for both distractor and nondistractor trials. Despite the lack of a significant delaydependent effect of drug treatment, on average, TV3326 improved accuracy most consistently during Short delay trials (Fig. 3) both for non-distractor and distractor trials. TV3326 does appear to have at least one advantage over methylphenidate in this task. Whereas methylphenidate exhibited clear efficacy in reversing distractor-induced decrements in task accuracy in young monkeys, the amphetamine derivative was unable to reverse distractor-induced performance decrements by aged subjects (Prendergast et al., 1998a) .
It is difficult to provide a level of comparison of the mnemonic effects of TV3326 relative to other drugs tested at this center owing to the lack of effect of the drug on task accuracy. However, the 25% improvement over baseline that was sustained in the titrating version of the DMTS task is in keeping with the most effective drugs that we have tested on an acute basis for improvements in standard DMTS accuracy. We have yet to determine whether such comparisons based on improvement over baseline performance for different task variables are valid. Where a more direct comparison may be made, is with regard to the most improved degree of accuracy associated with a delay interval (Short) for the non-distractor trials in the distractor version of the DMTS task. On average, the improvement amounted to 27.5% relative to vehicle levels of performance. Notwithstanding this limitation, these data provide at least a proof of concept that development of drugs with multiple targets and multiple pharmacological properties may prove superior to either monotherapy, or to combining drugs with varying pharmacokinetic properties in the treatment of neurodegenerative diseases. TV3326 represents a new class of drug at least potentially suited to the treatment of Alzheimer's disease patients who require therapies that will delay the progression of the disease, and who suffer from impaired attention, impaired memory, and depression. The combination of the properties attributed to an adrenergic agonist and to a cholinesterase inhibitor may derive benefit from their combined cognitive enhancing properties, as well as from the ability of adrenergic receptor activation to limit the side effects of cholinesterase inhibition (Buccafusco, 1992; Buccafusco and Terry, 2000; Paule, 2001) .
